NETRF Awards 13 Research Grants to Accelerate Neuroendocrine Cancer Treatments and Cures

The Neuroendocrine Tumor Research Foundation (NETRF) today announced its latest round of grant recipients for neuroendocrine cancer research. The thirteen investigators receiving awards are pursuing innovative, promising research that has the potential to improve the lives of those living with neuroendocrine cancer. Funding for these thirteen grants totals $2.8 million, bringing NETRF's all-time investment in research to nearly $43 million.

"NETRF has spent more than 20 years building powerful scientific momentum to improve treatments and outcomes for patients with neuroendocrine cancer," said Elyse Gellerman, NETRF's chief executive officer. "This year, we're pushing that progress even further-expanding our global investment in bold, innovative research to accelerate the breakthroughs patients urgently need."

The new awardees will focus on these themes in neuroendocrine cancer research:
1. Earlier, simpler detection and better diagnostic imaging
2. Personalized care guided by biomarkers and tumor signature
3. New targeted and combination therapies to improve effectiveness and reduce side effects
4. Overcoming resistance and preventing metastasis and progression
5. Immune-based therapies to mobilize the patient's immune system

In this new group of grantees, NETRF is funding five Investigator Awards, four Pilot Awards, three Mentored Research Awards, and one Accelerator Award, all focusing on basic and translational science. Nine of the thirteen awardees are first-time grant recipients of NETRF. The grant recipients are selected through a rigorous, competitive scientific peer-review process.

Research institutions receiving NETRF funding include Cancer Research Center of Lyon (France), Berlin Institute of Health at Charité (Germany), City of Hope, Columbia University, Dana-Farber Cancer Institute, the International Agency for Research on Cancer (IARC, France), Johns Hopkins University, Stanford University, TUM University Hospital Rechts der Isar (Germany), University of Bari Aldo Moro (Italy), University of California, Irvine, University of Colorado Anschutz Medical Campus, and University of Michigan.

"We're proud to support this dedicated global community of scientists at a time when research funding is increasingly uncertain," said Anna Greene, PhD, Chief Scientific Officer. "These researchers are making breakthroughs today that will speed the development of new therapies and, ultimately, cures for neuroendocrine cancer."

Since its founding in 2005, NETRF has funded 171 research projects at 81 institutions in 17 countries.

NETRF is grateful for the many individuals and foundations who support NETRF's research and education programs, including generous funding from The Margie and Robert E. Petersen Foundation, Elaine Nord, the Firsty Family and the extended Seltzer Family in memory of Julie Seltzer Firsty, Laura and Lew Moorman, and the Family and Friends of Diamond Brown.

NET Research Foundation
100 Hancock Street Third Floor
Quincy, MA 02171
(617) 946-1780 | info@netrf.org
Anne-Marie Green, Director of Communications - anne-marie.green@netrf.org

The mission of the Neuroendocrine Tumor Research Foundation (NETRF) is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. Get Involved, Donate, Learn More: Visit netrf.org.

This release was published on openPR.